KAPOSI-SARCOMA AND THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - TREATMENT WITH HIGH AND LOW-DOSES OF RECOMBINANT LEUKOCYTE-A INTERFERON
KAPOSI-SARCOMA AND THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - TREATMENT WITH HIGH AND LOW-DOSES OF RECOMBINANT LEUKOCYTE-A INTERFERON
复制标题
DOI：
10.1200/jco.1986.4.4.544
复制
发表时间：
1986-04-01
影响因子：
45.3
通讯作者：
KROWN, SE
中科院分区：
文献类型：
--
作者：
REAL, FX;OETTGEN, HF;KROWN, SE
The efficacy of recombinant leukocyte A interferon (rIFN-.alpha.A [Roferon-A, Hoffman-La Roche, Nutley, NJ]) treatment of Kaposi''s sarcoma in patients with acquired immunodeficiency syndrome was evaluated in sequential trials using high doses (36 .times. 106 units) and low doses (3 .times. 106 units) of interferon. A major response was seen in 38% of patients treated at the high dose, with a median response duration of 18 months. At the low dose, the major response rate was 3%; dose escalation to 36 .times. 106 units resulted in an additional major response rate of 17% in low-dose nonresponders, with a median response duration of 10 months. Four of 11 patients who achieved a complete response remain free of disease, whereas all partial responders have shown disease progression. Unacceptable toxicity occurred in 27% of patients initially treated at the high dose and only in 10% of those who had progressive dose escallation up to 36 .times. 106 units. Prior opportunistic infections correlated negatively with therapeutic response, whereas large tumor burden and gastrointestinal involvement did not. Responding patients showed a significantly longer survival and a lower incidence of subsequent opportunistic infections than nonresponders. However, from our study we cannot determine whether rIFN-.alpha.A has an effect on the natural history of Kaposi'' sarcoma in patients with the acquired immunodeficiency syndrome.
